Trial · NCT01517373
Results by group165
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 165
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | Placebo | Baseline (n=59, 57, 55, 60, 60) | 7.90 | Standard Deviation 0.988 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 10 mg | Baseline (n=59, 57, 55, 60, 60) | 7.97 | Standard Deviation 0.886 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 50 mg | Baseline (n=59, 57, 55, 60, 60) | 7.91 | Standard Deviation 0.987 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 100 mg | Baseline (n=59, 57, 55, 60, 60) | 7.88 | Standard Deviation 0.969 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | Glimepiride | Baseline (n=59, 57, 55, 60, 60) | 8.12 | Standard Deviation 0.884 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | Placebo | Change at Week 12 (n=56, 53, 53, 54, 54) | -0.13 | Standard Deviation 0.789 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 10 mg | Change at Week 12 (n=56, 53, 53, 54, 54) | -0.18 | Standard Deviation 0.804 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 50 mg | Change at Week 12 (n=56, 53, 53, 54, 54) | -0.45 | Standard Deviation 0.733 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | PF-04937319 100 mg | Change at Week 12 (n=56, 53, 53, 54, 54) | -0.64 | Standard Deviation 0.797 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 | Glimepiride | Change at Week 12 (n=56, 53, 53, 54, 54) | -1.01 | Standard Deviation 0.709 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | Placebo | Week 4 (n=58, 57, 55, 58, 60) | -0.08 | Standard Deviation 0.590 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 10 mg | Week 4 (n=58, 57, 55, 58, 60) | -0.07 | Standard Deviation 0.422 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 50 mg | Week 4 (n=58, 57, 55, 58, 60) | -0.22 | Standard Deviation 0.431 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 100 mg | Week 4 (n=58, 57, 55, 58, 60) | -0.32 | Standard Deviation 0.532 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | Glimepiride | Week 4 (n=58, 57, 55, 58, 60) | -0.54 | Standard Deviation 0.379 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | Placebo | Week 6 (n=57, 55, 55, 58, 55) | -0.14 | Standard Deviation 0.676 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 10 mg | Week 6 (n=57, 55, 55, 58, 55) | -0.14 | Standard Deviation 0.545 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 50 mg | Week 6 (n=57, 55, 55, 58, 55) | -0.22 | Standard Deviation 0.494 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | PF-04937319 100 mg | Week 6 (n=57, 55, 55, 58, 55) | -0.51 | Standard Deviation 0.479 | percentage of hemoglobin |
| Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8 | Glimepiride | Week 6 (n=57, 55, 55, 58, 55) | -0.78 | Standard Deviation 0.500 | percentage of hemoglobin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01517373/results